Teleflex Receives Innovative Technology Designation from Vizient for LMA® Gastro™ Airway
November 07 2017 - 6:45AM
Business Wire
Designation recognizes products that bring
improvements to the health care industry
Teleflex Incorporated (NYSE: TFX) announced its LMA® Gastro™
Airway has received a 2017 Innovative Technology designation from
Vizient, Inc., the largest member-driven health care performance
improvement company in the country. The designation was based on
direct feedback from hospital experts who interacted with LMA®
Gastro™ Airway at the Vizient Innovative Technology Exchange in
Denver on Sept. 14, 2017.
The LMA® Gastro™ Airway from Teleflex is the first laryngeal
mask specifically designed to enable clinicians to proactively
manage their patients’ airways while facilitating direct endoscopic
access via the integrated channel. With the airway in place,
clinicians can easily direct an endoscope and provide a patent
airway for patient safety, which can facilitate monitoring of end
tidal CO2.
The use of moderate-to-deep sedation during endoscopy is a
common practice. Respiratory depression from sedative drugs and
airway obstruction requiring intervention are known risks
associated with endoscopic procedures, with studies demonstrating
that hypoxemia can occur in 11-50% of cases.1-3 In the United
States there are more than 6.9 million upper endoscopies performed
each year.4 Today, many of these are undertaken without an airway
management device in place.
“Teleflex continues to develop innovative airway management
products through collaboration with clinicians around the world.
The introduction of LMA® Gastro™ provides a controlled airway
management solution for many higher risk patients undergoing
routine upper GI procedures,” said Justin McMurray, President and
General Manager, Teleflex Anesthesia and Emergency Medicine
Division. “We are honored to have the LMA® Gastro™ Airway
recognized as innovative technology by Vizient and look forward to
a continued relationship with Vizient and clinicians with a focus
on advancing clinical practice.”
“The Vizient Innovative Technology Exchange offers medical
technology suppliers the opportunity to demonstrate their products
and gain direct feedback from the approximately 1,500 clinical
experts who attend the event. Following exploration of the
technological capabilities of the LMA® Gastro™ Airway at the
Exchange, attendees recommended it receive an Innovative Technology
designation. Congratulations to Teleflex on receiving this status,”
said Debbie Archer, director of procurement and Vizient Innovative
Technology Program leader.
Vizient represents a diverse membership base that includes
academic medical centers, pediatric facilities, community
hospitals, integrated health delivery networks and non-acute health
care providers, with more than $100 billion in annual purchasing
volume. Through its Innovative Technology Program, Vizient works
with member-led councils and task forces to review potentially
innovative products. If it is determined that a product is
innovative, Vizient may award a contract outside of the competitive
bid cycle.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people's lives. We apply
purpose-driven innovation - a relentless pursuit of identifying
unmet clinical needs - to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference. For more information,
please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rüsch® and Weck® - trusted brands united by a common
sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Cuff Pilot, Deknatel, Hudson RCI,
LMA, LMA Gastro, Pilling, Rüsch, and Weck are trademarks or
registered trademarks of Teleflex Incorporated or its affiliates,
in the U.S. and/or other countries.
© 2017 Teleflex Incorporated. All rights reserved. MC-003914
References
- Cote GA, Hovis RM, Ansstas MA, et al.
Incidence of sedation-related complications with Propofol use
during advanced endoscopic procedures. Clin Gastroenterol Hepatol.
2010;8(2):137-142.
- Qadeer MA, Rocio Lopez A, Dumot JA,
Vargo JJ. Risk factors for hypoxemia during ambulatory
gastrointestinal endoscopy in ASA I-II patients. Dig Dis Sci.
2009;54(5):1035-1040.
- de Paulo GA, Martins FP, Macedo EP,
Goncalves ME, Mourao CA, Ferrari AP. Sedation in gastrointestinal
endoscopy: a prospective study comparing
nonanesthesiologist-administered Propofol and monitored anesthesia
care. Endosc Int Open. 2015;3(1):E7-E13.
- Peery AF, Dellon ES, Lund J, et al.
Burden of gastrointestinal disease in the United States: 2012
update. Gastroenterology. 2012;143(5):1179-1187 e1171-1173.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171107005145/en/
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024